Xtl Biopharmaceuticals (XTLB) Non-Current Deffered Revenue (2024)
Xtl Biopharmaceuticals (XTLB) posted quarterly Non-Current Deffered Revenue of $18000.0 for Q4 2024.
Xtl Biopharmaceuticals (XTLB) Non-Current Deffered Revenue (2024) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Non-Current Deffered Revenue for 1 consecutive years, with $18000.0 the latest figure, recorded in Q4 2024.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $18000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $18000.0 (changed N/A YoY) and the FY2024 annual result came in at $18000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue steadied at $18000.0 in Q4 2024 per XTLB's latest filing.
- Over the last five years, Non-Current Deffered Revenue for XTLB reached as high as $18000.0 in Q4 2024 and fell as low as $18000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Xtl Biopharmaceuticals | 2.60 Bn | 2.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 18,000.00 |